American Well Corporation (AMWL) Earnings Call Transcript
November 3, 2026
Earnings Call Speaker Segments
Good evening, everyone, and thank you for joining our Q3 earnings call. We continued to make steady progress this quarter. At the start of the year, we set a target for ourselves: reach positive cash flow from operations and positive adjusted EBITDA in Q4, and then build from there. For the quarter, both revenue and adjusted EBITDA came in above guidance. That makes nine consecutive quarters in which we've delivered on our commitments to you. We feel good about the quarter and about how the business is progressing, and we have solid visibility toward that fourth quarter goal. Mark will walk you through the numbers. Before that, let me talk about our market, our product, and what has been happening recently at our company. I'll begin with our customers, since their reality is what shapes everything we do. Health plans and employers are confronting their biggest cost increases in roughly 20 years. An additional 8%-11% rise in costs is projected for 2027. UnitedHealth said last month that costs are still stubbornly high across the whole healthcare landscape. Premiums aren't keeping up. The easy fixes have been used up. Technology-enabled care is among the few levers remaining, but only when it comes with proof. That pressure is reshaping the way health plans and employers buy. Access is no longer what they purchase. What they purchase is engagement and outcomes. Most of them now link digital health fees to performance. Close to half report that the programs they buy enroll under one in four eligible members. Weak engagement is now the number one reason they change vendors. Health plans and employers confront three big challenges in digital health right now. Vendor sprawl is the first, dozens of point solutions, each with a separate front door, expensive to connect, and difficult to compare. Member confusion is the second. A member who can't figure out where to begin won't begin. The third is missing proof. Seeing which programs work is hard, and replacing one without disrupting members is harder still. That sprawl keeps growing. Building a clinical program has become faster and cheaper thanks to AI. This year, hundreds of new digital health companies have secured investor funding, and a large share of them are AI-based. Our customers are under pressure to provide such programs, but each one comes with its own expenses, its own integration requirements, and its own separate entry point. The opportunity is real. So is the complexity. More and more, a member's route to care begins with talking to an AI assistant. Today, three in 10 adults consult AI tools for health information at least monthly, up from roughly one in six two years earlier. For our customers, the issue is where that conversation stops. It could stop at a guess. The outcome may be inappropriate care that harms the member and wastes plan resources—or it may be a covered in-network service suited to that member's needs, with proven clinical and financial results. Amwell is committed to fixing this for our customers. We help them secure improved clinical and financial outcomes. We do this through activation—drawing a larger portion of their members into technology-enabled care instead of conventional care, which often carries a higher price. We give our customers one platform, branded as their own, with a single integration. It delivers reliable, scalable rails for launching a program, sharing data with it, and evaluating its effectiveness. For the member, the experience stays consistent, simple, and engaging. A common data framework shows results and gets better at performing as time goes on. With AI beginning to transform healthcare, this platform becomes even more crucial. What we offer isn't an AI feature—we're the dependable platform where AI-assisted care runs with clinicians involved; we support our clients. We never vie with them. That's the reason big, advanced organizations trust us with their members. Altogether our customers account for more than 90 million covered lives; we handle the 9.6 million beneficiaries of the Military Health System, and the Department of Veterans Affairs has indicated it plans to do likewise. Two recent acknowledgments point the same way. In September, Frost & Sullivan honored Amwell for leadership in technology innovation. It pointed to how we can tackle the fragmentation in healthcare by means of a single, unified platform. Amwell was included by Time magazine on its list of the World's Top Health Tech Companies of 2026. Let me get specific about where our customers' focus lies for us at present. Six areas exist, and every one of them operates on the platform I just outlined. Three have to do with the member—bringing members in, what they see, and retaining them. Two have to do with the programs, both our partners' and our own. The final one is the data that demonstrates what works; for each, I'll lay out the problem and what we do about it today. First, activation. Value reaches a customer only when its members actually use the care it has purchased. The majority of health plans we speak with continue to report engagement that's only in the single digits. Our answer to that is always-on engagement—reaching members through our customers' own channels, staying within the rules those customers set. Once a customer turns it fully on, members use the platform at more than three times the rate we see when it's off. Value starts with activation. If activation doesn't happen, nothing else follows; when it does, members receive care, our customers achieve results, and we grow. The second point is the member experience. During this quarter, we delivered a dramatically improved experience to most of our key customers. Returning members now encounter three screens rather than 12. Members give their visits a rating of 4.9 out of five. The people delivering that experience are the clinicians within the Amwell Medical Group. Urgent care, virtual primary care, and behavioral health are among their offerings, along with nutrition and lactation programs. Beyond that, they serve as compassionate guides through a system that can be confusing. When a member needs to figure out the next step, they help with that decision, and they offer dependable reassurance, ease, and a human bond with a clinician—that's the experience we provide. Third is the continuing bond between the member and a clinician. At present, virtual care generally ends when the visit concludes. We invest in whatever happens both before and after the visit, so that the relationship endures and the member has a reason to come back. This matters to our customers since the clinician a member trusts acts as a strong referral pathway into whichever programs that customer has chosen. That's how activation grows over time. Number four is choice, and this is where programs come into play. A member ought to get the program that fits them, not just whatever happens to be on offer. With our standard process, a partner program goes live in a matter of weeks. A single sign-on, a single eligibility file, a single data connection, and a single report, all under the customer's brand. Customers can bring in a program or replace one without causing disruption for members — that's choice without the sprawl. Fifth is behavioral health, a space where demand keeps climbing while supply keeps falling short. SilverCloud, our behavioral health offering within the Amwell platform, handles evidence-based care delivery automatically and connects members to our in-house therapists and psychiatrists through that same platform. Evidence keeps accumulating. A case study we released last month with Discovery Health, among South Africa's biggest health plans, showed 22,000 members activated during the program's initial 12 months, with 90% of surveyed users reporting satisfaction.
When it comes to members dealing with moderate to severe depression, between 60% and 78% experienced clinically meaningful improvement. And during the year following use, mental health–related hospital costs for members came in 6% lower once other factors were adjusted for. Activation comes first, with measured outcomes supporting it. We prove things; we don't just claim them. Sixth and last, data. A shared data structure underpins everything I've described. It routes a member into a program armed with the right information. It gathers outcomes back and reports value in the customer's own terms — whether that customer is a health plan or an employer the plan serves. That's the way a program shows what it gives back for the money spent, and how it gets better as time goes on. Six areas, one platform. All together, they tackle the three problems I mentioned at the start: too many vendors, members who are confused, and no evidence. That is where we're concentrated for customers right now, and it's where we'll keep putting resources. Now let me turn to our government business, starting with the Department of Veterans Affairs; in September, we said the department had issued a letter of intent for us to roll out the Amwell platform throughout its enterprise. The department serves more than 9 million veterans. I want to be exact about what this is. The letter is not a binding contract. We still need to negotiate and execute a definitive agreement under federal procurement rules, and that effort is already in progress. The letter followed a thorough evaluation. It pointed to scalable video consultations, interoperability, cybersecurity compliance, and backing for integrated care delivery; simply put, the capabilities the Department assessed are ones we already run at scale for the Military Health System, and the Department's own scale is substantial. During fiscal 2025, more than 2.9 million veterans used its telehealth services, and it provided over 11.7 million video visits to the home. That trust honors us, and we are preparing for this work carefully. Alongside the Defense Health Agency, we keep serving the Military Health System without interruption. We're in talks on that direct, longer-term contract—the one the agency told us in June it plans to award. Before I wrap up, there are two principles that shape how we operate this company. The first one is discipline. We're committed to continuing to enhance efficiency and effectiveness throughout the business. We expect the same standards of ourselves that we promise our customers. We verify results before we take credit for them. The second one is focus. We're narrowing our work around one differentiated Amwell platform. A single platform gives our customers greater reliability, extends more quickly, and costs less to operate; that's what enables everything I've described. In short, the market is heading toward what we've built. Artificial intelligence is expanding the range of programs our customers are able to provide. Our platform is the dependable method for delivering those programs to members and for demonstrating which ones are effective. Virtual care for the Military Health System operates on it. The Department of Veterans Affairs has signaled that it intends to do the same, and we are executing all of this with discipline; we have strong visibility into positive cash flow from operations as well as positive adjusted EBITDA in the fourth quarter; having said that, I will turn the call over to Mark, who will walk you through our operational and financial results. Mark.
Thanks, Ido, and good afternoon, everyone. I'll start today's call with the third-quarter highlights, then go through our financial results in detail, and finish with our outlook for the fourth quarter and the full year. In the third quarter, our revenue came in above the high end of our guidance range, and adjusted EBITDA landed toward the high end of our range. The outperformance was driven mainly by visit volumes that were stronger than expected and continued cost discipline. These results keep us on track toward our goal of generating positive cash flow from operations in the fourth quarter of this year. For the third quarter, total revenue came in at $49 million, which represents a roughly 12.9% decrease compared with the same period last year, though it landed $1 million above the top end of our guidance range. Subscription revenue reached $23.9 million, a decline of about 22.5% year-over-year and about 6.8% quarter-over-quarter. That year-over-year drop continues to stem from the churn we previously disclosed and have discussed on earlier earnings calls. Revenue from Amwell Medical Group, or AMG, visits was $23.7 million, an increase of approximately 11.7% year-over-year but a decrease of roughly 3.1% sequentially, which mirrors the usual seasonal pattern in visit volumes. On the AMG side, we had roughly 301,000 visits, which was basically flat compared with a year ago. Revenue per visit came in at about $79, an increase of around $8 per visit, or 11%, versus the third quarter of last year. That gain comes from better pricing and volume in urgent care, plus our visit mix continuing to move toward higher-value clinical programs. Virtual primary care visits rose about 41% year over year and are still on a strong growth path. Platform visits overall were approximately 760,000, a decline of roughly 30.5% year over year, in line with the portfolio changes we've already discussed. Gross profit was $26 million at a 53% gross margin, up about 57 basis points from a year ago, when it was 52.4% in the third quarter of 2025. The gain compared with a year earlier came from keeping costs in check and from greater revenue in our clinical programs. As we have mentioned, the revenue mix we have now will probably yield a margin profile in line with recent quarters, and we still expect that mix to move toward SaaS offerings with higher margins as time goes on. Total operating expenses, depreciation and amortization included, came to $37.6 million, roughly 36.1% lower than a year earlier and roughly 1.3% higher than the prior quarter. Operating expenses as a share of revenue improved to 76.8%, versus 104.5% in the third quarter of last year and 71.3% in the last quarter. The improvement over the prior year reflects gains from our transformation actions, reduced litigation costs, and ongoing cost discipline throughout the business. For the third quarter, adjusted EBITDA came in at a loss of $3.6 million, which compares with a loss of $12.7 million in Q3 of 2025 — that works out to a $9.1 million improvement. Operating loss was $11.7 million versus an operating loss of $29.3 million in the third quarter of 2025, roughly a 60% improvement. Amwell's balance sheet remains in a very strong position. We closed the quarter with about $181 million in cash and investments and no debt, and we anticipate a very similar position at year-end. Turning to guidance: for Q4 2026, we expect revenue in the range of $48 million to $50 million, with adjusted EBITDA from break-even up to + $1 million. This guidance accounts for the typical seasonal uptick in visit volume that comes with winter, along with continued stability in our subscriber base. Turning to the full year, we are raising our outlook. We now expect full-year 2026 revenue of $204 million to $206 million, compared with the prior range of $195 million to $205 million. For full-year adjusted EBITDA, we now anticipate a loss of $6.9 million to $7.9 million, a substantial improvement from the earlier forecast of a $12 million to $16 million loss. Full-year AMG visits are still anticipated to come in at the top of the previously communicated range of 1.32 million to 1.37 million visits. Our Q4 guidance assumes adjusted EBITDA ranging from break-even to positive, consistent with objectives we have outlined previously. In closing, third-quarter revenue came in above the guidance we had issued, driven by increased visit volumes, a steady subscription base, and a more efficient cost structure — which positions us well to finish the year on a strong note. I want to express my gratitude to all of my colleagues, who are unquestionably Amwell's most valuable asset, for their ongoing hard work and commitment. With that, I'll return the call to Ido.
Thank you, Mark. Before we get to your questions, I want to recap the key points. In 2026 we found clarity, focus, and urgency in addressing what our customers need but aren't getting. Clients are staring down the steepest cost hikes they've seen in 20 years; buying access is no longer what they do. What they buy is engagement and outcomes. AI is multiplying the number of programs they can offer. That delivers genuine opportunity along with genuine complexity. Amwell provides a single platform under their own brand through a single integration; we bring in members; we deliver an experience that is simple and consistent. We match them with the right program, and we demonstrate results; what we sell is not an AI feature. We are the trusted platform on which AI-powered care operates with clinicians kept in the loop. We serve as an extension of our clients. Competing with them is never what we do. Virtual care for the Military Health System operates on our platform. The Department of Veterans Affairs has indicated it intends to follow. We run this company with discipline and focus. We exceeded our guidance this quarter; that makes nine quarters straight of meeting our commitments, and we have solid visibility toward positive cash flow from operations and positive adjusted EBITDA in the fourth quarter. I take pride in our team and am thankful for how they met this challenge with agility and passion. Our strategic and operational focus on the mission is sharper than it has ever been. Much has been accomplished. Significant work lies ahead, and we are devoted to the path we are on and to growing shareholder value. With that, we'll open the call for your questions. Operator, please go ahead.
Hello there, and good evening. Thanks for letting me ask a couple of things. To start with the VA: could you take us through how these negotiations actually work? What milestones come next, and what's the right way to think about it across this year, or possibly the following one? Are you expecting any kind of contract terms within this year, or next year? How should we frame that?
What we're in now is highly granular discussion, and it comes after a very lengthy process — the outcome of which was the letter of intent that we received and then published. Turning that overall direction into a complete contract plus a work plan is just as detailed an effort, yet we're quite hopeful we'll reach that point. I won't try to predict the timing, though we don't believe it will drag on very long. A great deal of ground has already been covered, and — this matters a lot — the VA is delighted to observe that our platform has demonstrated it works in an environment closely resembling its own. We're reasonably confident you won't be waiting very long for this project, and after that we certainly intend to carry out a rather thorough implementation early in the coming year; how long it runs and when it goes live genuinely hinges on specifications that aren't entirely settled yet.
Got it. Regarding the DHA, there’s clearly a possible new contract that’s on the horizon. I suppose this has two parts. First, before you perhaps ink the new contract, what occurs with the current one? Is there some runoff or any kind of contingency under which the preexisting contract keeps running? Could you help us connect the outgoing contract with the potential new one and explain how we ought to think about that? Thanks.
Certainly. With the DHA, we are in full production across the board. Since going live, the system has performed very well with no issues—at least none we know about—and I believe our conversations with the customer reflect that at present. As Mark has mentioned in various opportunities previously, we fully anticipate converting the present agreement into another one—a longer-term arrangement that, given the DHA’s preference, could be a direct agreement with Amwell. And naturally, once that takes place, we will share it with everybody.
Understood. Thanks.
Yeah, thank you. Regarding the commercial side, given your shift in emphasis toward payers, what’s landing best with those customers right now, and what kinds of expansion possibilities do you foresee ahead?
Hi, Craig. Thanks. You’re definitely right that the bulk of our major chance lies in that area between commercial payers and government, which in many respects functions like a payer, where risk matters enormously. As I said in my prepared remarks today, there’s a strong focus on clinical and financial outcomes, and achieving those demands activation, plus cutting the operational expenses tied to vendor sprawl and how that turns into missing outcomes or the possibility of harming outcomes. It seems quite evident to us that in conversations with customers—both existing and new—having a single platform that needs just one integration, creates one straightforward engaging experience with substantial flexibility to add any program and to measure whether it works, comes across as extremely compelling. We hear that repeatedly. As you likely know, much of payers’ infrastructure is now constrained by budget limits. Vendor sprawl remains as large as ever. Employers and others want more programs, yet the capacity to deliver that without a platform is severely compromised. We slot perfectly into this situation. Our growth possibilities fall into two areas. First—and this is extremely significant—is sales growth. We haven’t even begun to scratch the surface. All of us, the whole industry, sit in the single digits of activation, and so many people could benefit from the service that’s already covered for them and readily available. We know they love it once they use it. They simply aren’t aware of it and aren’t active for various reasons. That’s somewhere we see plenty of opportunity. The fact that our own marketing, for instance, can deliver 3x on traditional alternative options is again extremely encouraging. We fully anticipate growth in how many members use our platform. Very importantly, given how the platform operates with different investment, the sophistication level and breadth, along with the parts of the continuum of care we can provide, will likely expand a great deal. Mark mentioned earlier that our virtual primary care alone—which is far broader than urgent care, traditional urgent care—grew more than 40%. We believe this represents a trend, and we see the value per member, along with the member count, as highly promising growth opportunities for the company. Beyond that, naturally, there remain quite a few payers and a significant number of sizable government agencies that are not currently part of our client base, and in those areas we clearly observe a healthy pipeline increase and a rising level of interest. Incidentally, these two things reinforce each other, since when our existing customers report improved outcomes, lower costs, and generally high member satisfaction, that immediately feeds into the sales cycle and the appetite level of their peers. That is genuinely how we view it.
Understood. So as a follow-up, when you start putting the 2027 budget together, could you touch on how much visibility you have into growth at this point in the year compared with a year ago, and also any other main areas of investment or efficiencies you expect to drive?
Obviously, we've made some significant investments in the government sectors, and the results hinge on factors at play right now, which we're optimistic will conclude very, very well; we're confident that revenue quality is improving at the company and that the pipeline is growing. Naturally, we aren't giving guidance for next year; we'll likely do that on the next earnings call, and I think that's the right moment to share more color on exactly how next year will play out.
Got it. Thank you.
Hello. Nice work on a solid quarter. Could you speak to what you expect for EBITDA in the fourth quarter? It appears you're guiding toward roughly break even. Should we expect that pattern to carry on into 2027? Many thanks.
Hey, Dave. Appreciate the nice remarks. We actually have solid visibility into EBITDA for this fourth quarter now underway. We're confident we'll hit our objective — one we've had for a long time now — of breaking even on EBITDA. We'll probably land on the positive side, the upper end of the range we gave. A substantial amount of impact will obviously decide whether we stay at a break-even pace across the various quarters of 2027, and that hinges on the timing and receipt of a — hopefully — new VA contract and on the effect of any extension of a standalone direct contract with the DHA. As Ido mentioned, guidance for the full year 2027 comes on February 16th. That said, at present we're executing toward, and feel very confident about, finishing the year with EBITDA positive results for the quarter and a cash balance of roughly $180 million.
Sorry if I overlooked this, but how much additional revenue do you anticipate between 2026 and 2027 from the VA and/or the DHA, and what would make up that increase, if anything?
Correct; no specifics were provided by us regarding that increase. Clearly, whatever comes from the VA will be additive, given that we have never brought in any revenue from the VA before, and the DHA contract is most likely to be finished this quarter, in its final stages.
Does the VA start on 01/01/2027?
No, that isn't determined at this point. Talks with the VA are ongoing. Things are much more advanced with the DHA, though we're hopeful that we'll clearly get something signed with the VA within the next couple of months.
All right. Great job on the progress you're achieving. Well done.
Thanks once more.
Thank you, Dave. Thank you very much.
Thank you, and congratulations on the strong quarter and the VA LOI too. I'd like to ask about something: last quarter you mentioned backing a return to growth without any meaningful rise in headcount. Would that still be true if the VA opportunity materializes? I'm trying to work out how much you can leverage the federal infrastructure you already have in place versus having to invest ahead of deployment? Maybe just offer some color on that.
Hi, Jailendra. Quite a few factors feed into our profitability. As our numbers show, we went a very long way toward focusing the company on the Amwell platform, defining what matters and what doesn't, and divesting or de-emphasizing everything else. We also overhauled the workflows and processes across the company, with and without AI, to deliver strong efficiency and effectiveness. That trend is ongoing, and we fully expect to keep this process moving forward. We are very much restructuring the company. To answer your question directly, we don't expect any significant growth, even with the large contracts, beyond something immaterial or dramatic, thanks to the efficiencies; that doesn't mean we won't give these new contracts our full attention. We absolutely will. We have dedicated teams; we have plans to serve it and to keep serving it well. But efficiencies from other things we stopped doing and things we now do far more efficiently will sustain a very disciplined cost structure for the company.
That’s clear. Just one quick follow-up from me on subscription revenue. After it fell what, 7% in Q3, Mark, you’re now describing Q4 as stable. Does that mean we’ve basically hit the floor on subscription revenue, and at this point—I’m not asking for 2027 guidance—but could you just say that directionally we should probably begin to see sequential growth from here, since hopefully all that churn is largely behind us?
Jailendra, I’d say the churn we’ve been seeing has probably come from those components. You’ll begin to see much less churn related to any health plan impact, but for the other businesses that we’ve decided we’re no longer focused on and have de-emphasized, I assume we’ll still have some amount of natural churn. As for the big swings that may have occurred in 2025 and 2024, you’re definitely right. We don’t expect any further activity of that kind going forward.
Got it. Thanks a lot.
You're welcome.
Yeah. Appreciate you taking the question, and congratulations on the progress, guys. Maybe I could build on a few of the earlier questions. Mark, I believe last quarter you laid out a kind of target — if all the opportunities in the pipeline sort of pan out, we could think of maybe mid-teens as a reasonable growth target for next year. With the progress you're making right now, is that still the framework we should be thinking about? If not, how should we think about next year in that sense?
Yeah. Hi, Charles. During our previous call, we felt strongly that solid headway was being made on a number of the bigger opportunities. With the year now nearly over, the start dates on those new opportunities have shifted into 2027 rather than kicking off on January 1 of 2027. Although we have confidence that some of that growth will materialize, we recognize it won't affect the full calendar year. Even so, our pipeline remains stronger than it has ever been, and all we need is for those contract start dates to arrive as soon as they can.
Alright, that's helpful. Could you speak to — you mentioned a number of cases earlier where patient experience has improved and outcomes are getting better. That obviously backs up the sales pipeline, because other customers witness those results and then come to Amwell. Does it also generate organic, same-store sales, if you will? Perhaps you could walk through how the results you deliver have driven organic sales at customers you already have? How much growth this year, maybe, has come from that, and how much of it should we factor in as part of building toward next year and future revenue growth? Thanks.
Hi, Charles. You're absolutely right. A handful of the investments we've made are beginning to become quite visible in the numbers, and every one of them holds substantial growth potential. Let me offer a few concrete examples. This year, we significantly enhanced our engagement capabilities, and although I've mentioned that before, it remains a very nice number. We know that when we execute on that, engagement improves 3x, which is very good; on top of that, we just introduced a new experience for members, and we saw NPS and ratings climb, as they noted earlier, to 4.9 out of five. I believe that's among the highest, if not the highest, we've ever seen, and that as well has a direct link to engagement. Our infrastructure can now bring a partner on board in a matter of weeks rather than the many months it used to take, and our goal is to get that down to days. This matters a great deal, since it lets our customers try out many new programs and link them to various accounts. It benefits our relationships with the national accounts and other employers, and it is also highly valuable for improving outcomes. Alongside our data investment, this makes results far more transparent and simple for people to grasp. Consider that, as things stand, engagement sits in the single digits. To put it less optimistically, more than 90%—at times 97% or 98%—of the addressable population derives no benefit from technology-enabled care. I mean not just urgent care but the full range of services. And I don't mean only AMG, which is growing so much stronger and matters so greatly for navigation and trust and for the relationship with patients. I mean all those numerous programs to which they can refer. So with 90 million covered lives, there is enormous opportunity. I'm not even discussing the potential expansion in government, which is very important. I won't speculate about how fast that moves, but the upside is clearly very, very substantial. Building on my earlier remarks, there's a strong likelihood—bordering on near certainty—that we will bring a substantial number of new customers on board, which should expand the pool of prospects we can serve. My sense is that our pricing approach is going to change and develop over time, shifting away from conventional SaaS subscription arrangements and leaning more and more toward charging based on outcomes, directly linked to traction. The adjustments we've made allow us to shoulder a greater portion of risk alongside our customers, and delivering stronger results also opens a considerably bigger opportunity for us to claim an appropriate portion of the MLR via the savings we generate. Overall, I would describe the company today as keenly concentrated on an extremely well-defined value proposition. That value proposition is landing well. It offers a route to meaningful multi-year growth. To be clear, the precise dynamics in this area, over the coming months and so forth, are something we'll discuss on the next call.
And just to make sure I've got this right — I understand AMG is a part of your business that's driven by volume, but for the rest of your business, when engagement goes up, meaning more of the covered lives are engaging with Amwell, does that bring in more revenue for the company, or are customers paying for what amounts to a fixed level of usage? Thanks.
Absolutely. Basically, my view is that when you look several years ahead from now, most of what we do will involve clinical services that win and deliver the outcomes. The SaaS piece may not necessarily shrink significantly, but relative to the clinical revenue, the clinical services that deliver the outcome will become smaller. We think a great deal of the upside lies in utilization, where we share the results with our customers.
Great. Thanks, guys.
Hi, Matt Shea here, filling in for Ryan. Appreciate you taking our questions. To build a bit on what Charles asked, the member experience and the upgrade you rolled out this quarter seemed like a notable highlight and possibly an important enhancement for driving member engagement. But I'm curious, when did it actually go live at most clients? Was it earlier in the quarter or later on? And it sounds like the qualitative feedback has been strong, but is there any quantitative evidence yet, such as visits per member or repeat visit rates, or what metrics would be best to track going forward, I suppose, to measure the success of the member experience overhaul?
Matt, that upgrade came fairly recently, and while you saw a good number of our investments pay off in the figures Mark discussed, what we're definitely seeing is early days with very encouraging results. You still don't see much of that impact in the numbers today.
All right. And which metrics would you say are the best ones to keep an eye on from here, to sort of measure how well things are going?
Yes. Thanks for bringing that up. Clinical revenue at times comes via direct use of various AMG services, virtual primary care. Behavioral health is something we feel very, very confident about; we mentioned SilverCloud. Internationally, our outcomes were excellent. Now we're putting money into bringing it fully into the United States, with substantial investments, and our expectations there are high. AMG services will get far more efficient and far more appealing. On top of that, there are partners and third-party clinical program utilization that produces an attractive margin, where essentially we drive traffic their way along with information, gather information, and return it to the payer in one unified form. In our view, that revenue stream stands a good chance of being a very meaningful growth driver down the road. In our opinion, both of these will expand considerably faster than the SaaS recurring revenue, given a world in which our customers are extremely, extremely focused on the outcomes.
Great, that helps. Regarding the DHA contract, I believe you'd earlier estimated the behavioral health opportunity at 15%-20% or more of platform value, with next year being the soonest it could be activated. Is reinstatement something being addressed within the current direct contract negotiation, or should we view it as a separate procurement opportunity later on? I'm just trying to understand how that fits into your 2027 opportunity set.
Right now, our attention is on the current infrastructure that is in play and works really well. You are absolutely correct that we proved in this environment that our behavioral services deliver very good results, but that's a full upside opportunity that we believe is separate from the current dialogue.
Got it. Thanks, Ido.
You're welcome, Matt.
Thanks, Trace, and thanks to all of you. We're grateful for the backing you give Amwell, and we appreciate your being with us tonight.
This does conclude the program. You may now disconnect.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete American Well Corporation transcript - plus 131,000+ transcripts from 7,000+ companies, speaker segments and full-text search - through the EarningsAPI REST API or hosted MCP server.
Get an API key View API docs →For developers and AI pipelines
Programmatic access to American Well Corporation earnings transcripts and 131,000+ others is available through the
EarningsAPI REST API and the hosted MCP server.
Quarterly plans from $162 - full transcripts, speaker segments, full-text search,
and the /api/v1/transcripts/recent polling endpoint for ETL pipelines.